Recent Company News

• 05:52 AM ET Sep 03, 2026
  

  Transcript Intelligence: Aspen Pharmacare Holdings Q4 Earnings Guidance

• 05:52 AM ET Sep 03, 2026
  

  Transcript Intelligence: Aspen Pharmacare Holdings Q4 Earnings Themes

• 05:52 AM ET Sep 03, 2026
  

  Transcript Intelligence: Aspen Pharmacare Holdings Q4 Earnings Q&A

• 07:12 AM ET Sep 02, 2026
  

  Aspen Pharmacare Holdings reports FY NHEPS continuing ops ZAR 8.02 vs guidance (21-Aug) between ZAR 7.84-8.17 (ZAR 156.47, -0.03)

• 01:58 AM ET Sep 02, 2026
  

  Aspen Pharmacare Holdings plans to cancel repurchased shares (ZAR 156.50, 0.00)

• 03:28 AM ET Aug 31, 2026
  

  Amgen presents, publishes new findings on Repatha at ESC Congress 2026 ($432.42, 0.00)

• 08:06 AM ET Aug 21, 2026
  

  Aspen Pharmacare Holdings guides FY NHEPS continuing ops between ZAR 7.84-8.17 vs year-ago ZAR 6.59 and FactSet ZAR7.54 (ZAR 144.95, +1.31)

• 09:03 AM ET Jul 29, 2026
  

  Positive CHMP opinion by the EMA supports broader use of Amgen's REPATHA before a first heart attack or stroke ($393.10, 0.00)

• 06:48 AM ET Jul 24, 2026
  

  Merck announces initial access plans for Alimatravir ($130.48, 0.00)

• 06:24 AM ET Jul 24, 2026
  

  EU's CHMP adopted positive opinion recommending change to terms of marketing authorisation for medicinal product Repatha ($371.50, 0.00)